Researchers evaluated the primary mechanisms governing drug resistance and relapse in patients treated with crenolanib, an FLT3 inhibitor.
The study also looked at how lenalidomide maintenance further increases the rate of negative MRD results in multiple myeloma patients.
A phase I study examines the use of LCAR-B38M, a CAR T-cell therapy directed against BCMA, in patients with relapsed/refractory multiple myeloma.
Is the continuation of maintenance rituximab beneficial post bendamustine plus rituximab treatment in FL Patients?
A study investigates whether FL patients had fewer early disease progression events when assigned to treatment with obinutuzumab plus chemotherapy.
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
Dr. Daver discusses immunotherapy approaches for patients with acute myeloid leukemia (AML), and his recent study results on the combination of azacitidine and nivolumab.
Guidelines for cancer screening in survivors of childhood HL may be refined based on the results of this extended follow-up study, say the researchers.
Researchers reported on the impact of adding the Hedgehog pathway inhibitor glasdegib to low-dose cytarabine.
A new study published in Cancer compared ELN-2017 to ELN-2010 in terms of distinguishing prognosis in younger patients with newly diagosed AML.